Outlook Therapeutics (NASDAQ:OTLK) Price Target Cut to $3.00 by Analysts at HC Wainwright

Outlook Therapeutics (NASDAQ:OTLK - Get Free Report) had its target price cut by HC Wainwright from $30.00 to $3.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has a "buy" rating on the stock. HC Wainwright's price target indicates a potential upside of 92.31% from the company's current price. HC Wainwright also issued estimates for Outlook Therapeutics' Q2 2025 earnings at ($0.60) EPS, Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($2.33) EPS, Q1 2026 earnings at ($0.21) EPS, Q2 2026 earnings at ($0.32) EPS, Q3 2026 earnings at ($0.26) EPS, Q4 2026 earnings at ($0.16) EPS, FY2026 earnings at ($0.95) EPS, FY2027 earnings at $0.62 EPS, FY2028 earnings at $2.37 EPS and FY2029 earnings at $3.24 EPS.

A number of other research firms have also recently weighed in on OTLK. Guggenheim restated a "buy" rating and issued a $12.00 price target on shares of Outlook Therapeutics in a research note on Friday, January 17th. Chardan Capital restated a "neutral" rating on shares of Outlook Therapeutics in a research note on Monday, December 2nd. Finally, BTIG Research dropped their price target on Outlook Therapeutics from $50.00 to $9.00 and set a "buy" rating on the stock in a research note on Friday, November 29th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $12.00.

Outlook Therapeutics Trading Down 4.9 %

Shares of Outlook Therapeutics stock traded down $0.08 on Tuesday, reaching $1.56. 753,835 shares of the company were exchanged, compared to its average volume of 613,068. Outlook Therapeutics has a one year low of $0.87 and a one year high of $12.85. The company has a market capitalization of $49.95 million, a price-to-earnings ratio of -0.21 and a beta of 0.58. The company has a 50-day moving average of $1.89 and a 200 day moving average of $4.33.

Outlook Therapeutics (NASDAQ:OTLK - Get Free Report) last announced its quarterly earnings data on Friday, February 14th. The company reported ($0.89) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.04). Analysts predict that Outlook Therapeutics will post -2.27 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. grew its holdings in Outlook Therapeutics by 34,936.7% in the 4th quarter. Russell Investments Group Ltd. now owns 17,168 shares of the company's stock valued at $32,000 after buying an additional 17,119 shares in the last quarter. Commonwealth Equity Services LLC acquired a new position in Outlook Therapeutics in the 4th quarter valued at $48,000. Jane Street Group LLC grew its holdings in Outlook Therapeutics by 133.9% in the 4th quarter. Jane Street Group LLC now owns 26,218 shares of the company's stock valued at $50,000 after buying an additional 15,008 shares in the last quarter. Christensen King & Associates Investment Services Inc. acquired a new position in Outlook Therapeutics in the 3rd quarter valued at $55,000. Finally, Bank of New York Mellon Corp grew its holdings in Outlook Therapeutics by 44.8% in the 4th quarter. Bank of New York Mellon Corp now owns 29,764 shares of the company's stock valued at $56,000 after buying an additional 9,211 shares in the last quarter. 11.20% of the stock is owned by institutional investors and hedge funds.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.